Sanofi-Aventis U.S. LLC has secured FDA approval for SARCLISA ESCENA (isatuximab-irfc), the subcutaneous formulation of the multiple-myeloma therapy. This development enhances the company's commercial portfolio and introduces a potentially more patient-friendly alternative to the intravenous version, positioning the drug to capture incremental market share in the relapsed or refractory multiple myeloma space.